When GETomics meets aging and exercise in COPD
The term GETomics has been recently proposed to illustrate that human health and disease are actually the final outcome of many dynamic, interacting and cumulative gene (G) – environment (E) interactions that occur through the lifetime (T) of the individual. According to this new paradigm, the final outcome of any GxE interactions depends on both the age of the individual at which such GxE interaction occurs as well as on the previous, cumulative history of previous GxE interactions through the induction of epigenetic changes and immune memory (both lasting overtime).
Autores: D. Pellegrino, S. Casas-Recasens, R. Faner, P. Palange, A. Agusti.
Puedes leer el artículo entero aquí: https://www.resmedjournal.com/article/S0954-6111(23)00182-8/fulltext
Noticias relacionadas
TRIPLE THERAPY AND CLINICAL CONTROL IN B+ COPD PATIENTS: A PRAGMATIC, PROSPECTIVE, RANDOMIZED TRIAL
Treatment with LABA/LAMA is recommended in GOLD B patients. We hypothesized that triple therapy (LABA/LAMA/ICS) will be superior to LABA/LAMA in achieving and maintaining clinical control
COPD in the 21st Century
COPD in the 21st Century: Alvar Agustì and Rosa Faner are part of this book, being authors of chapter 4. Scientists and clinicians across many countries have made great efforts to understand this important disease, and these have yielded positive results.
Coffee Talk: CADSET-explaining the lung function tracker tool
The latest episode of Coffee Talk sees co-chairs of the ERS Clinical Research Collaboration CADSET, Prof. Erik Melén and Prof. Rosa Faner, catch up to discuss the topic of the new lung function tracker tool.
Más artículos
COPD
- 759785·Richard Beasley et Al – Prevalence, Diagnostic Utility and Associated Characteristics of Bronchodilator Responsiveness
- 759788·Alvar Agustí, Rod Hughes, Eleni Rapsomaki, Barry Make, Ricardo Del Olmo, Alberto Papi, David Price, Laura Benton, Stefan Franzen, Jørgen Vestbo, Hana Mullerova – The many faces of COPD in real life: a longitudinal analysis of the NOVELTY cohort
- 759883·Alberto Papi, Rosa Faner, Ian Pavord, Federico Baraldi, Vanessa M McDonald, Mike Thomas, Marc Miravitlles, Nicholas Roche, Alvar Agustí. – From treatable traits to GETomics in airway disease: moving towards clinical practice
- 768799·Surya P Bhatt Richard Casaburi Alvar Agusti et Al. Chronic obstructive pulmonary disease: hiding in plain sight, a Statement from the COPD Foundation Medical and Scientific Advisory Committee
- 768885·Miguel Angel Martinez-García, Alvar Agustí. – Microbiological Monitoring in Therapeutic Trials in Chronic Obstructive Pulmonary Disease
Recuerda que puedes acceder a varios enlaces a artículos dentro de la categoría EPOC en esta web. También puedes acceder otros enlaces en el Listado de Artículos de la Cátedra de Salud Respiratoria.
Imágenes y texto obtenidos de la publicación original
